Drug development in systemic sclerosis: novel therapeutics to watch
A key breakthrough is the emergence of cell‑based immunotherapies, bispecific antibodies, and next‑generation small molecules that extend beyond adaptive immune targets to modulate innate immunity directly. Collectively, these agents illustrate a unifying concept: successful disease modification will require the synchronous interception of inflammation, fibrotic remodeling, and vascular injury rather than approaching these domains independently.
Authors
- Francesco Annunziato (ORCID: https://orcid.org/0000-0001-8798-7589)
- Raffaella Molteni (ORCID: https://orcid.org/0000-0002-5481-7572)
- Lorenzo DAGNA
- Jelena Colic
- Veronica Batani
- Corrado Campochiaro
- Giacomo De Luca
- Giulia Bandini
- Cristina Scaletti
- Marco Matucci-Cerinic
Institutions
- University of Modena and Reggio Emilia (IT)
- Vita-Salute San Raffaele University (IT)
- Karolinska Institutet (SE)
- University of Belgrade (RS)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University of Florence (IT)
Publication Details
- Journal
- Expert Review of Clinical Immunology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1080/1744666x.2026.2636654
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00